Type: Agonistic (immunostimulatory) humanized monoclonal antibody designed to bind to an epitope on CD73, an antigen known to be involved in lymphocyte migration and activation.
Status: Corvus said July 7 that it launched a Phase I trial (NCT04464395) assessing CPI-006’s novel immunotherapy approach in patients with mild to moderate COVID-19, following FDA acceptance of the company’s IND application. The open-label, Phase I study is expected to enroll up to 30 patients who will receive a single dose of CPI-006, with levels of 0.3, 1.0, 3.0 and 5.0 mg/kg, escalating in four cohorts as the study progresses. The first cohort of five patients has been treated at Temple University Hospital in Philadelphia. The study is expected to enroll up to 30 patients at several sites in the U.S.
The study’s primary efficacy endpoint is the change in serum immunoglobulin (IgM and IgG) anti-SARS-CoV-2 levels compared to baseline at day 28.
According to Corvus, CPI-006 has shown binding to various immune cells and the inducement of a humoral adaptive immune response—B cell activation and lymphocyte trafficking leading to the production of antigen-specific immunoglobulin (IgM and IgG) antibodies, based on in vitro and in vivo studies in cancer patients. CPI-006 has also led to increased levels of memory B cells.
Corvus asserted that CPI-006’s production of antibodies and memory cells to pathogens such as SARS-CoV-2 may provide immediate and long-term clinical benefits for patients including shortened recovery time and improved long-term protective immunity.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: